Pioneering Medical Innovations
A new analysis of the SYMPHONY-PE Trial suggests early thrombectomy may improve key measures of heart recovery in intermediate-risk pulmonary embolism patients.
Imperative Care initiated the ADAPT 2.0 study evaluating an advanced clinical technique designed to simplify acute ischemic stroke treatment.
The company initiated the CLEAR-IT clinical study targeting gaps in clinical standards for peripheral thromboembolism.
SOL-1 met its superiority primary endpoint, the first successful demonstration of superiority in an FDA-aligned wet AMD trial comparing a novel investigative agent to an approved anti-VEGF treatment.
Ocular announced it would report topline SOL-1 Phase 3 data on February 17, 2026, with detailed data to follow at the 49th Macula Society Annual Meeting.
The first peer-reviewed clinical data on the allay Hydrogel Cap was published in Plastic and Reconstructive Surgery, Global Open, in a paper on early clinical experience treating and preventing symptomatic neuroma.
Late-breaking, real-world data from a multi-center review of stroke patients treated with the ADAPT 2.0 technique using the Zoom Stroke System were presented at the SVIN 2025 annual meeting.
Tulavi announced an expanded indication for the allay Hydrogel Cap covering patients weighing 25 kg (55 lbs) and above, extending its reach to smaller patients at risk of symptomatic neuromas.
Positive efficacy and safety results from the pivotal SYMPHONY-PE Trial were presented at The PERT Consortium symposium and published in Circulation: Cardiovascular Interventions, with no mortality and no device-related serious adverse events.
The FDA cleared the Symphony Thrombectomy System, the first large-bore continuous vacuum system for treating pulmonary embolism.